GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Cessation of Dr Simrat Sohal as Other of the company w.e.f. August 05, 2026.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Dr. Simrat Sohal, who served as Compliance Officer and Senior Management Personnel. She will step down effective close of business hours on 5th August 2026. Dr. Sohal is leaving to pursue new career opportunities outside the company. The company has confirmed her commitment to ensuring a smooth transition and completing handover responsibilities during her notice period. This disclosure is made under Regulation 30 of the SEBI Listing Regulations, 2015. The resignation letter was submitted on 19th May 2026, with an internal confirmation from management acknowledging her decision.
The departure of the Compliance Officer is a significant governance change. While the company has adequate notice period until August 2026 to identify and onboard a replacement, investors should monitor for the appointment of a new Compliance Officer, as this role is critical for regulatory compliance under SEBI regulations.